Global healthcare major Novo Nordisk India has announced a strategic partnership with Pune-based Emcure Pharmaceuticals Ltd. to commercialise Poviztra® (semaglutide injection 2.4 mg) in India — marking it as the second brand of Wegovy®, Novo Nordisk’s globally acclaimed weight-loss medication.
Under this collaboration, Emcure Pharma becomes the first Indian pharmaceutical company to secure exclusive rights for the distribution and commercialisation of Poviztra® in India. The partnership is aimed at expanding access to Novo Nordisk’s innovative semaglutide molecule for individuals living with overweight and obesity across the country, especially in regions beyond Novo Nordisk’s existing network.
Launched in India in June 2025, Wegovy® (semaglutide 2.4 mg) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management and for lowering cardiovascular risk in people with obesity. Clinical trials have shown that one in three users of Wegovy® experienced over 20% weight loss.
“Obesity is a serious chronic disease affecting millions of people across India,” said Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk. “With this partnership, we aim to make our GLP-1–based obesity treatment more accessible by leveraging Emcure’s strong distribution and marketing capabilities.”
Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, said the company is proud to introduce the world’s most trusted GLP-1–based weight-loss molecule to India.
“With our deep market understanding and strong national reach, we aim to ensure that Poviztra® reaches patients who need it most,” Mehta added.
Semaglutide (marketed as Wegovy®/Poviztra®) has been extensively studied under global obesity programmes such as STEP and SELECT. The molecule has nearly a decade of clinical use and over 38 million patient years of real-world exposure. The once-weekly injection is available in five dosage strengths (0.25 mg to 2.4 mg) and comes in a pen device designed for ease of administration and dosing precision.
According to The Lancet Diabetes & Endocrinology (2023), India has nearly 254 million adults with generalised obesity and another 351 million with abdominal obesity, making access to long-term, evidence-based weight management solutions a growing national priority.
